Your browser doesn't support javascript.
loading
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
Mehnert, Janice M; Bergsland, Emily; O'Neil, Bert H; Santoro, Armando; Schellens, Jan H M; Cohen, Roger B; Doi, Toshihiko; Ott, Patrick A; Pishvaian, Michael J; Puzanov, Igor; Aung, Kyaw L; Hsu, Chiun; Le Tourneau, Christophe; Hollebecque, Antoine; Élez, Elena; Tamura, Kenji; Gould, Marlena; Yang, Ping; Stein, Karen; Piha-Paul, Sarina A.
Afiliación
  • Mehnert JM; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
  • Bergsland E; University of California at San Francisco, San Francisco, California.
  • O'Neil BH; Simon Cancer Center, Indiana University, Indianapolis, Indiana.
  • Santoro A; Humanitas Clinical and Research Center IRCCS, Rozzano (Mi), Italy.
  • Schellens JHM; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Cohen RB; Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Doi T; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Ott PA; University of Pennsylvania, Philadelphia, Pennsylvania.
  • Pishvaian MJ; National Cancer Center Hospital East, Chiba, Japan.
  • Puzanov I; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Aung KL; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
  • Hsu C; Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Le Tourneau C; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Hollebecque A; National Taiwan University Hospital, Taipei, Taiwan.
  • Élez E; Department of Drug Development and Innovation, Curie Institute, Paris & Saint-Cloud, France.
  • Tamura K; INSERM U900 Research Unit, Curie Institute, Saint-Cloud, France.
  • Gould M; Versailles-Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux, France.
  • Yang P; Gustave Roussy Institute of Oncology Cancer Center, Villejuif, France.
  • Stein K; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Piha-Paul SA; National Cancer Center Hospital, Tokyo, Japan.
Cancer ; 126(13): 3021-3030, 2020 07 01.
Article en En | MEDLINE | ID: mdl-32320048
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Tumor Carcinoide / Tumores Neuroendocrinos / Anticuerpos Monoclonales Humanizados / Receptor de Muerte Celular Programada 1 / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2020 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Tumor Carcinoide / Tumores Neuroendocrinos / Anticuerpos Monoclonales Humanizados / Receptor de Muerte Celular Programada 1 / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2020 Tipo del documento: Article